| Literature DB >> 33953970 |
Lin Wang1,2, Mulalibieke Heizhati1, Xintian Cai1, Mei Li1, Zhikang Yang1, Zhongrong Wang1, Reyila Abudereyimu1, Nanfang Li1.
Abstract
BACKGROUND: This study aims to evaluate the risk factors associated with untreated hypertension and develop and internally validate untreated risk nomograms in patients with hypertension among primary health care of less developed Northwest China.Entities:
Year: 2021 PMID: 33953970 PMCID: PMC8062209 DOI: 10.1155/2021/6613231
Source DB: PubMed Journal: Int J Hypertens Impact factor: 2.420
Figure 1The flow chart of inclusion and screening of surveyed subjects.
Baseline characteristics of the study population by training set and validation set.
| Variables | Training set ( | Validation set ( | Total ( |
|
|---|---|---|---|---|
| Age (years) | 52.63 ± 17.61 | 52.69 ± 17.26 | 52.65 ± 17.49 | 0.963 |
| <45 y | 191 (30.5) | 77 (28.6) | 268 (29.9) | 0.820‡ |
| 45–60 y | 201 (32.1) | 91 (33.8) | 292 (32.6) | |
| >60 y | 234 (37.4) | 101 (37.5) | 335 (37.5) | |
|
| ||||
| Gender, women ( | 337 (53.8) | 135 (50.2) | 472 (52.7) | 0.316# |
| Herdsman ( | 260 (41.5) | 116 (43.1) | 376 (42.0) | 0.659# |
|
| ||||
| Education levels ( | ||||
| Primary and lower | 361 (57.7) | 159 (59.1) | 520 (58.1) | 0.923‡ |
| Junior high | 145 (23.2) | 60 ( 22.3) | 205 (22.9) | |
| Senior high and higher | 120 (19.2) | 50 (18.6) | 170(19.0) | |
|
| ||||
| Ethnicity ( | ||||
| Han | 269 (43.0) | 111 (41.3) | 380 (42.5) | 0.198# |
| Kazakh | 90 (14.4) | 54 (20.1) | 144 (16.1) | |
| Tajik | 74 (11.8) | 28 (10.4) | 102 (11.4) | |
| Others | 193 (30.8) | 76 (28.3) | 269 (30.1) | |
|
| ||||
| Number of family members ( | ||||
| 1 | 33 (5.3) | 10 (3.7) | 43 (4.8) | 0.551‡ |
| 2–4 | 403 (64.4) | 172 (63.9) | 575 (64.3) | |
| ≥5 | 190 (30.4) | 87 (32.3) | 277 (30.9) | |
|
| ||||
| Marital status ( | ||||
| Single | 64 ( 10.2) | 21 (7.8) | 85 (9.5) | 0.508# |
| Married | 511 (81.6) | 224 (83.3) | 735 (82.1) | |
| Separated | 51 (8.1) | 24 (8.9) | 75 (8.4) | |
|
| ||||
| Family income per member | ||||
| <¥500/month | 142 (22.7) | 65 (24.2) | 207 (23.1) | 0.004‡ |
| ¥500–1000/month | 73 (11.7) | 30 (11.2) | 103 (11.5) | |
| ¥1001–3000/month | 286 (45.7) | 146 (54.3) | 432 (48.3) | |
| >¥3000/month | 125 (20.0) | 28 (10.4) | 153 (17.1) | |
|
| ||||
| Altitude of habitation (m) | ||||
| <1000 | 387 (61.8) | 164 (61.0) | 551 (61.6) | 0.717‡ |
| 1000–3000 | 163 (26.0) | 76 (28.3) | 239 (26.7) | |
| >3000 | 76 (12.1) | 29 (10.8) | 105 (11.7) | |
|
| ||||
| Current smokers ( | 150 (24.0) | 50 (18.6) | 200 (22.3) | 0.077# |
| Current drinkers ( | 138 (22.0) | 46 (17.1) | 184 (20.6) | 0.093# |
|
| ||||
| Body mass index | 27.29 ± 4.30 | 27.25 ± 4.48 | 27.28 ± 4.35 | 0.917 |
| BMI: <23.9 kg/m2 | 124 (19.8) | 53 (19.7) | 177 (19.8) | 0.669‡ |
| BMI: 24.0–27.9 kg/m2 | 242 (38.7) | 112 (41.6) | 354 (39.6) | |
| BMI: ≥28.0 kg/m2 | 260 (41.5) | 104 (38.7) | 364 (40.7) | |
|
| ||||
| Abdominal obesity (n, %) | 424 (67.7) | 183 (68.0) | 607 (67.8%) | 0.930# |
| CVD ( | 21 (3.4) | 2 (0.7) | 23 (2.6) | 0.195# |
| Diabetes ( | 91 (14.5) | 31 (11.5) | 122 (13.6) | 0.228# |
| Dyslipidemia ( | 113 (18.1) | 41 (15.2) | 154 (17.2) | 0.307# |
| Comorbidity ( | 193 (30.8) | 66 (24.5) | 259 (28.9) | 0.057# |
|
| ||||
| Blood pressure (mmHg) | ||||
| Systolic blood pressure | 149.37 ± 20.58 | 152.09 ± 21.34 | 150.19 ± 20.83 | 0.073 |
| Diastolic blood pressure | 85.67 ± 12.31 | 85.97 ± 13.68 | 85.76 ± 12.73 | 0.749 |
CVD, cardiovascular disease. Student's t-test for continuous variables. ‡Mann-Whitney U test for ordered multicategorical variables. #Chi-square test for binary variables.
Figure 2Demographic features, socioeconomic status, live setting, health-related behaviors, and anthropometric value selection using the LASSO binary logistic regression model. (a) Optimal parameter (lambda) selection in the LASSO model used fivefold cross-validation via minimum criteria. The partial likelihood deviance (binomial deviance) curve was plotted versus log (lambda). Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the 1-SE of the minimum criteria (the 1-SE criteria). (b) LASSO coefficient profiles of the 17 features. A coefficient profile plot was produced against the log (lambda) sequence. Vertical line was drawn at the value selected using fivefold cross-validation, where optimal lambda resulted in five features with nonzero coefficients. LASSO: least absolute shrinkage and selection operator; SE: standard error.
Prediction factors for nontreatment in hypertension from study population by multiple logistic regression model.
| Stratification |
| OR (95% CI) |
|
|---|---|---|---|
| Age | 0.517 | 1.68 (1.27–2.21) | <0.001 |
| Herdsman | 1.054 | 2.87 (1.77–4.64) | <0.001 |
| Family income per member | −1.644 | 0.19 (0.15–0.25) | <0.001 |
| Altitude of habitation | 1.134 | 3.11 (2.17–4.44) | <0.001 |
| Comorbidity | −0.776 | 0.46 (0.27–0.78) | 0.004 |
| Constant | −1.920 | 0.147 | <0.001 |
OR: odds ratio; CI: confidence interval.
Figure 3Developed medication nontreatment nomogram.
Figure 4Receiver operating characteristic curve of the untreated nomogram prediction in the study.
Figure 5Calibration curves of the nomogram in the training set (a) and validation set (b). The x-axis represents the predicted untreated risk. The y-axis represents the actual identified untreated patients. The diagonal dotted line represents a perfect prediction by an ideal model. The solid line represents the performance of the nomogram, of which a closer fit to the diagonal dotted line represents a better prediction.
Figure 6Decision curve analysis for the untreated nomogram. The y-axis measures the net benefit. The red line represents the medication untreated risk nomogram. The thin solid line represents the assumption that all patients are nontreatment to medication. Thin thick solid line represents the assumption that no patients are nontreatment to medication. The decision curve showed that if the threshold probability of a patient ranges from 7% to 91%, using this untreated nomogram in the current study to predict medication nontreatment risk adds more benefit than the intervention-all-patients scheme or the intervention-none scheme.